10 March 2023 - - The "Plasmid DNA Contract Manufacturing Market Size, Share & Trends Analysis Report By Application (Cell & Gene Therapy, Immunotherapy), By Therapeutic Area (Cancer, Infectious Diseases), By End-user, By Region, And Segment Forecasts, 2023 - 2030" report has been added to Dublin-based ResearchAndMarkets.com's offering.

The global plasmid DNA contract manufacturing market size is expected to reach 1,117.5 m by 2030, registering a CAGR of 19.3%.

Companies Mentioned

Lonza
Charles River Laboratories
Vgxi, Inc.
Plasmid Factory GmbH & Co. Kg
Boehringer Ingelheim Bioxellence
Biocina
Thermofisher Scientific Inc.
Vive Biotech
Trilink Biotechnologies
Esco Aster Pte. Ltd

The growing popularity of cell & gene therapy, prevalence of chronic diseases is increasing and plasmid DNA has a wide range of uses in the healthcare sector are the key factors driving the growth of the market.

The field of gene therapy significantly broaden the treatment of viral infections, malignancies, hereditary illnesses, and immunotherapy.

The therapy is, however, not yet widely used in clinical settings, and licenses have often only been given in particular countries.

Examples of gene treatments include Spinraza, which is used to treat spinal muscular atrophy.

However, government assistance, assuring sustainability, community involvement, enacting suitable regulatory legislation, and promoting entrepreneurship are vital to the success of any gene therapy programs in Africa.

Hence, the growing adoption of gene therapy in the treatment of cancer is propelling the growth of the plasmid DNA contract manufacturing market.

However, the COVID-19 resulted into positive impact on the plasmid DNA contract manufacturing market.

There was an increase in demand for vaccines during the COVID-19 pandemic. The market would certainly benefit from the efforts of biotechnology companies that produce COVID-19 vaccines made from plasmid DNA.

In 2022, it is anticipated that the incidence of COVID-19 would increase, thus advancing the need for COVID-19 vaccinations.

For instance, India recently became the first country in the world to approve a COVID-19 DNA plasmid vaccine. The ZyCoV-D vaccine has received the Drugs Controller General of India's emergency clearance, making it the sixth vaccine to receive approval in India.

Furthermore, it is the only vaccine that has been approved for adolescents between the ages of 12 and 18.

The fact that a DNA vaccination has been authorized for use in people for the first time, according to researchers from all around the world, makes the approval significant.

Cell & gene therapy dominated the market with a revenue share of 60.3% in 2022. The growing confidence of people in the dependability, efficiency, and safety of gene treatments in the treatment of a wide range of chronic and genetic disorders drives the growth of the segment.

Based on therapeutic areas, cancer dominated the segment with a revenue share of 39.0% in 2022. The growing number of cancer cases increases the demand for cancer treatment therapies.

Pharmaceutical and biotechnology Companies dominated the market with a revenue share of 59.2% in 2022.

There is a growing demand for innovative therapies requiring plasmid DNA. The companies investing in research also help to propel the segment market.

Asia Pacific is anticipated to register the fastest CAGR growth of 19.9% during the forecast period.

The high burden of diseases, growing cancer cases, and growing adoption of plasmid DNA for developing vaccines and drugs for various diseases are the key factors driving the growth of the market in the region.